The Department of Clinical Haematology is a specialized clinical and academic unit headed by Dr. Nitin Gupta who is a DM in Clinical Hematology from AIIMS New Delhi and then did a fellowship in leukemia/Bone marrow transplant from Vancouver, Canada. He has been associated with this hospital since 2014. He has been instrumental in developing and running adult bone marrow and stem cell transplant program.
Department of clinical hematology is dedicated to provide comprehensive care for patients with benign and malignant disorders of the blood and bone marrow. The department is committed to advancing hematology through high-quality patient care, structured academic training, and meaningful research. The department integrates evidence-based diagnostics, state-of-the-art therapeutics, and a multidisciplinary approach to deliver patient-centred outcomes.
The department manages a wide spectrum of hematological disorders, including:
Specialized services include:
Bone marrow/Hematopoietic Stem Cell Transplantation:Department of Clinical hematology has long established its name in the field of hematopoietic stem cell transplantation, including both autologous, allogeneic, haploidentical and unrelated donor transplants. Department has a state of art 4 bedded stem cell transplant unit since 2017. We are among the first few centres to start haploidentical (half matched) transplants in 2015 in our old bone marrow transplant unit way before the current stem cell centre became functional. For patients without a HLA matched family donor for transplant, unrelated donor transplants is an option. We are associated with unrelated donor registries like DATRI of India and DKMS from Germany. Our transplant cost is one of the most affordable in country in private sector and our results are at par with any other centre in country. In last 4 years we have done almost 200 transplants as follows.
Day-care centre: Clinical hematology has a 6 bedded day care unit which is the back bone of our patient’s care. Procedure like Bone marrow aspiration and biopsy, chemotherapy, immunotherapy, blood products transfusion are routinely there. Patient can get their treatments/ procedure done in day time and then goes back to their home without the need of staying overnight. Standardized treatment protocols aligned with national and international guidelines are followed, supported by regular audits to ensure safety, efficacy, and quality outcomes.
The department runs one of the oldest and most sought-after running DNB (now Dr. NB) training Program in Clinical hematology since 2010 which takes two candidates each year. Until now 20 Clinical Hematologists have been trained by us who are serving in different parts of India and carrying the Sir Ganga Ram Hospital's legacy forward. We have started a one-year fellowship program in clinical hematology for overseas students. Our teaching activities include
Fellow (2025): Dr. Surendra Prasad Shah (Nepal)
The department works in close coordination with hematopathology, transfusion medicine, flow cytometry, cytogenetics, and molecular diagnostics laboratories. This integration enables:
These facilities also provide a strong platform for postgraduate and fellowship training in advanced diagnostic techniques.
Research is a core focus of the department, with active involvement in:
Clinical trials: Dr. Nitin Gupta (Principal Investigator)
Faculty and trainees regularly publish in peer-reviewed journals and present their work regularly at national and international scientific meetings.
1. Gupta, N., Verma, M., Gupta, D. et al. Post-transplant Cyclophosphamide (PTCY) Based GVHD Prophylaxis in Matched Hematopoietic Stem Cell Transplant: A Retrospective Study. Indian J Hematol Blood Transfus (2025). https://doi.org/10.1007/s12288-025-02241-2
2. Mondal S, Gupta D, Vairamoorthy N, Moule P, Kotwal J, Gupta N. Azacytidine and Venetoclax as a Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia: A Single Centre Experience. Indian J Hematol Blood Transfus. 2025 Jan;41(1):197-199.
3. Purohit KA, Kotwal J, Gupta N, Sharma A, Dass J. Immune cell subset variations in immune thrombocytopenia: a prospective observational study. J Hematop. 2025 Sep 9;18(1):41. doi: 10.1007/s12308-025-00656-4. PMID: 40921890.
4. Verma M, Gupta N, Dass J, Arya V, Gupta D, Saraf A, Langer S, Kotwal J, Sharma A. Applicability of Hscore and Adapted HLH 2004 for Diagnosis of Adult HLH in Indian population-A Prospective Study. Indian J Hematol Blood Transfus. 2025 Jul;41(3):622-628. doi: 10.1007/s12288-024-01902-y
5. Moule P, Gupta D, Agarwal C, Langer S, Saraf A, Kotwal J, Gupta N. Congenital Dyserythropoietic Anaemia Type II with SEC23B Mutation in Adults: A Case Series. Indian J Hematol Blood Transfus. 2025 Jan;41(1):203-206. doi: 10.1007/s12288-024-01806-x.
6. Gupta, D., Moule, P., Aggarwal, C., Kotwal, J., Langer, S., Saraf, A., & Gupta, N. (2024). Improved Outcome of Primary Plasma Cell Leukemia in the Current Era with the Use of Novel Agents and Autologous Bone Marrow Transplants—A Single Centre Experience. Indian Journal of Hematology and Blood Transfusion.
7. Gupta, D., Moule, P., Ranjan, V. et al. Clinical Profile, Treatment and Outcome of Thrombotic Thrombocytopenia Purpura (TTP) in Rituximab Era- an Experience from Tertiary Care Centre from North India. Indian J Hematol Blood Transfus (2024). https://doi.org/10.1007/s12288-024-01775-1
8. Gupta D, Arya V, Dass J, Gupta N, Kalra M, Sachdeva A, Kotwal J. Assessment of the phenotypic severity of hemophilia A: using rotational thromboelastometry (ROTEM) and APTT-clot waveform analysis. Blood Res. 2024 May 14;59(1):19. doi: 10.1007/s44313-024-00018-6. PMID: 38743166; PMCID: PMC11093952.
9. Vairamoorthy N, Mondal S, Bansal N, Mishra N, Kotwal J, Gupta N. A Second Course of Horse ATG in Patients with Relapsed Severe Aplastic Anaemia - A Case Series. Indian J Hematol Blood Transfus. 2025 Oct;41(4):1002-1004. doi: 10.1007/s12288-024-01950-4.
10. Balasubramanian, R., Gupta, P., Moule, P. Sharma A, Kotwal J, Gupta N. Amyloid Secreting Jejunal Plasmacytoma. Indian J Hematol Blood Transfus (2024). https://doi.org/10.1007/s12288-024-01762-6
11. Moule, P., Langer, S., Kotwal, J., Gupta, D., Agarwal, C., & Gupta, N. (2024). Synchronous dual haematological malignancies – Multiple myeloma and low-grade B-cell lymphoma – A case report and review of the literature. Current Medicine Research and Practice.
12. Dahiya S, Kotwal J, Langer S, Saraf A, Prakhar P, Gupta D, Gupta N, Arya V. Acute panmylelosis with myelofibrosis - A rare case report with review of literature. Indian J PatholMicrobiol. 2024 Feb 19. doi: 10.4103/ijpm.ijpm_391_23.
13. Moule P, Langer S, Gupta D, Agarwal C, Gupta N, Kotwal J. A case of MonoMAC syndrome prototype of GATA2 mutation a multimodality and multispecialty diagnosis. Indian J PatholMicrobiol. 2024 Mar 25. doi: 10.4103/ijpm.ijpm_502_23. Epub ahead of print. PMID: 38563709.
14. Moule, P., Gupta, D., Agarwal, C. et al. Treatment and Outcome of Light Chain Deposition Disease in the Era of Novel Agents and Transplant. Indian J Hematol Blood Transfus (2023). https://doi.org/10.1007/s12288-023-01681-y
15. Moule, P., Langer, S., Gupta, N., & Kotwal, J. (2023). Mono-dysplasia score based on automated cell counter (Sysmex) – A novel parameter for differentiating reactive monocytosis from hematological malignancies. Journal of Applied Hematology, 14, 187 - 193.
16. Mishra, N., Langer, S., Ak, B., Gupta, N., & Kotwal, J. (2023). An unexpected cause of refractory thrombocytopenia in post renal transplant patient. Journal of Clinical Images and Medical Case Reports.
17. Dass J, Langer S, Kotwal J, Gupta N. The Journey of Primary Myelofibrosis to Splenic Marginal Zone Lymphoma on the Wheels of Ruxolitinib. Indian J Hematol Blood Transfus. 2021;37(1):186-188. doi:10.1007/s12288-020-01320-w
Title:
Application of Next-Generation Sequencing (NGS)-Based Genetic Analysis in Newly Diagnosed Multiple Myeloma: Implications for Prognosis and Personalized Therapy
Vision and Future Goals
The department aims to further strengthen its core focus on cure of serious blood diseases using cutting edge cellular therapies, bispecific antibody and targeted therapies, postgraduate and fellowship training, expand research output, enhance access to advanced diagnostics, and contribute meaningfully to national standards in hematology care and education.
Key Focus Areas for the Coming Years:
